Dr. Ilias Karaiskos | Public Health | Best Researcher Award

1st Department of Internal Medicine-Infectious Diseases |  Hygeia hospital, Athens | Greece

Dr. Ilias Karaiskos is a distinguished physician and clinical researcher specializing in internal medicine and infectious diseases at the 1st Department of Internal Medicine, Hygeia General Hospital, Athens, Greece. Working under the leadership of Professor H. Giamarellou, he has contributed extensively to the management of complex infections, infection control, and antimicrobial stewardship within one of Greece’s most advanced and internationally accredited healthcare institutions. Dr. Karaiskos’s research focuses on antimicrobial pharmacokinetics, multidrug-resistant pathogens, and optimized antibiotic therapy in critically ill patients. His doctoral work on the pharmacokinetics of colistin significantly influenced global clinical practice, forming part of the International Consensus Guidelines for the Optimal Use of Polymyxins. Recognized by the Hellenic Society for Infectious Diseases with the Best PhD Award (2015), his research has shaped antibiotic dosing strategies that improve patient outcomes and reduce antimicrobial resistance. With over 80 peer-reviewed publications and an h-index of 39, Dr. Karaiskos has amassed more than 5,600 citations through collaborative studies with leading European and global research consortia, including the EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). His recent works address the efficacy of novel β-lactamase inhibitors, pharmacokinetics of ceftazidime-avibactam in renal replacement therapy, and strategies for infection control in intensive care settings. Through his clinical leadership, academic collaborations, and evidence-based research, Dr. Karaiskos continues to advance the global fight against antimicrobial resistance, shaping policies and treatment guidelines that enhance the quality and safety of infectious disease management worldwide.

Featured Publications

1. Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Karaiskos, I., … (2019). International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and others. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 39(1), 10–39. Citations: 949

2. Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Karaiskos, I., … (2009). Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrobial Agents and Chemotherapy, 53(8), 3430–3436. Citations: 637

3. Gutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hsueh, P. R., Viale, P., Karaiskos, I., … (2017). Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. The Lancet Infectious Diseases, 17(7), 726–734. Citations: 545

4. Karaiskos, I., & Giamarellou, H. (2014). Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: Current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy, 15(10), 1351–1370. Citations: 435

5. Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019). The “old” and the “new” antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Frontiers in Public Health, 7, 151. Citations: 328